Food and Drugs Administration

Biological Response Modifiers Advisory Committee

October 10, 2002


Retroviral Insertional Mutagenesis and Cancer in Animal Models, Dr. Linda Wolff, PhD, NIH  HTM  Ppt

AML in Mice After Retroviral Cell Marking  HTM  Ppt

Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy,  Dr. Stuart Orkin, MD and Dr. Amo Motulsky, MD  HTM  Ppt

Treatment of Patients With Persistent Immune Defects Despite Allogeneic Bone Marrow Transplantation  HTM  Ppt

Self-Inactivating LTRs and Chromatin Insulators, Philippe Leboulch, Genetix Pharmaceuticals, Inc.  PDF